Akebia Therapeutics (AKBA) Return on Capital Employed (2014 - 2026)

Akebia Therapeutics (AKBA) has 13 years of Return on Capital Employed data on file, last reported at 2.7% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 2.7%, up 1535.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2.7% (up 1535.0% YoY), and the FY2025 annual result was 17.32%, up 5091.0% from the prior year.
• Return on Capital Employed eased to 2.7% in Q1 2026 per AKBA's latest filing, from 11.33% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 11.33% in Q4 2025 and troughed at 93.53% in Q1 2022.
• A 5-year average of 27.1% and a median of 29.85% in 2022 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed sank 1110 bps in 2022, then surged 7326 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 29.85% in 2022, then fell by 12 bps to 33.4% in 2023, then dropped by 14 bps to 37.95% in 2024, then jumped by 130 bps to 11.33% in 2025, then plunged by 76 bps to 2.7% in 2026.
• Business Quant data shows AKBA's Return on Capital Employed at 2.7% in Q1 2026, 11.33% in Q4 2025, and 8.01% in Q3 2025.